9th Sep 2014 11:46
LONDON (Alliance News) - Akers Biosciences Inc has signed a sales contract for its Tri-Cholesterol "Check" product covering Australia, Singapore, the United Arab Emirates and Oman.
The rapid diagnostic screening and testing products maker said the USD864,000 contract will be handled by Dubai-based 36 Strategies General Trading LLC and will target customers from the military, medical, university and resources sectors.
The Tri-Cholesterol "Check" is a finger-stick blood sample technology which provides both total and high-density lipoprotein cholesterol levels in patients.
"This order gives us confidence that this test could become a very important and widely used test worldwide," said Akers Executive Chairman
Akers shares were up 19% to 255 pence on Tuesday, putting it among the top five risers in the AIM All-Share index.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
AKR.L